LXRX — Lexicon Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $556.50m
- $338.07m
- $1.20m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | |
Standards: | USG | USG | USG | USG | — |
Status: | Final | Final | Final | Final | fx Preliminary |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 272 | 152 | 86.7 | 138 | — |
Net Total Accounts Receivable | |||||
Net Total Receivables | 56.5 | 0.395 | 0.014 | 0.028 | — |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 338 | 158 | 88.9 | 141 | — |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 15.7 | 1.5 | 3.48 | 4.37 | — |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 418 | 204 | 137 | 194 | — |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 65.3 | 46.8 | 22.1 | 23.2 | — |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 301 | 47.4 | 23.3 | 77.2 | — |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 117 | 156 | 114 | 117 | — |
Total Liabilities & Shareholders' Equity | 418 | 204 | 137 | 194 | — |
Total Common Shares Outstanding |